Sunshine Guojian Pharmaceutical (Shanghai)'s weak ROE and ne...

Sunshine Guojian Pharmaceutical (Shanghai)'s weak ROE and net income decline may negatively affect the share price due to low earnings retention or inadequate capital allocation. Despite the industry's 11% growth over a 5-year period, the company's progress lags behind. Analysts predict a slight improvement in the company's earnings growth.